Neumora Therapeutics Inc [NMRA] stock prices are up 0.74% to $13.64 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The NMRA shares have gain 16.48% over the last week, with a monthly amount drifted -12.06%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Neumora Therapeutics Inc [NASDAQ: NMRA] stock has seen the most recent analyst activity on November 05, 2024, when JP Morgan downgraded its rating to a Neutral and also revised its price target to $15 from $18. Previously, H.C. Wainwright started tracking the stock with Buy rating on October 01, 2024, and set its price target to $30. On July 22, 2024, Needham initiated with a Buy rating and assigned a price target of $23 on the stock. Mizuho started tracking the stock assigning a Outperform rating and suggested a price target of $20 on July 08, 2024. Deutsche Bank initiated its recommendation with a Hold and recommended $13 as its price target on December 12, 2023. William Blair started tracking with a Outperform rating for this stock on October 10, 2023, and assigned it a price target of $26. In a note dated October 10, 2023, Stifel initiated an Buy rating and provided a target price of $26 on this stock.
The stock price of Neumora Therapeutics Inc [NMRA] has been fluctuating between $8.33 and $21.00 over the past year. Currently, Wall Street analysts expect the stock to reach $24.5 within the next 12 months. Neumora Therapeutics Inc [NASDAQ: NMRA] shares were valued at $13.64 at the most recent close of the market. An investor can expect a potential return of 79.62% based on the average NMRA price forecast.
Analyzing the NMRA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.68, Equity is -0.61 and Total Capital is -0.77. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.37 points at the first support level, and at 13.10 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.00, and for the 2nd resistance point, it is at 14.36.
Ratios To Look Out For
It’s worth pointing out that Neumora Therapeutics Inc [NASDAQ:NMRA]’s Current Ratio is 17.22. Further, the Quick Ratio stands at 17.22, while the Cash Ratio is 6.52.
Transactions by insiders
Recent insider trading involved Fust Matthew K, Director, that happened on Oct 18 ’24 when 14049.0 shares were sold. Director, Fust Matthew K completed a deal on Oct 17 ’24 to sell 7739.0 shares. Meanwhile, Director Fust Matthew K bought 14049.0 shares on Oct 18 ’24.
